CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Pre-Launch

canagliflozin; metformin hydrochloride

ANDAORALTABLET

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE (canagliflozin; metformin hydrochloride) by Zydus Lifesciences is sglt2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Approved for established cardiovascular disease ( ), nonfatal myocardial infarction, nonfatal stroke) in adults with type 2 diabetes mellitus and 6 more indications.

Drug data last refreshed 14h ago

Mechanism of Action

SGLT2, expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for…

Indications (9)

established cardiovascular disease ( )

Worked on CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE at Zydus Lifesciences? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.